Drug Trial Radar · NCT00259376
American-Australian-African Trial With Dronedarone in Patients With Atrial Fibrillation or Atrial Flutter for the Maintenance of Sinus Rhythm
Last checked: Nov 19, 2026Latest source record: Feb 15, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
629
Actual
Start
Nov 2001
Primary completion
Sep 2003
Study completion Sep 2003
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Nov 29, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess the efficacy of dronedarone versus placebo for the maintenance of normal sinus rhythm after electrical, pharmacological or spontaneous conversion of atrial fibrillation/atrial flutter (AF/AFL). To assess the efficacy of dronedarone versus placebo on ventricular rate control in case of AF/AFL recurrence. To assess the efficacy of dronedarone versus placebo on AF/AFL-related symptoms.
Conditions
- Atrial Fibrillation
- Atrial Flutter
Interventions
Dronedarone (SR33589)Drug
oral administration
placeboDrug
oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary endpoint of the study is the time from randomisation to first documented AF/AFL recurrence
Locations
5 sites in 5 countries. Site status is shown where the registry gives one.
Sanofi-Aventis Administrative Office
Bridgewater, New Jersey
Sanofi-Aventis Administrative Office
Buenos Aires, Argentina
sanofi-aventis Australia administrative office
Macquarie Park, Australia
Sanofi-Aventis Administrative Office
Laval, Canada
Sanofi-Aventis Administrative Office
Midrand, South Africa
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.